Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions. Authors' reply.
사설/논평
0/5 보강
APA
Aceituno L, Vogel A, Sapisochin G (2026). Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions. Authors' reply.. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70590
MLA
Aceituno L, et al.. "Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions. Authors' reply.." Alimentary pharmacology & therapeutics, 2026.
PMID
41795135 ↗
같은 제1저자의 인용 많은 논문 (4)
- Perioperative immunotherapy to reduce recurrence in resectable hepatocellular carcinoma - lessons learned from the CARES-009 trial.
- Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.
- Beyond rejection risk: Identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC.
- The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.